K. Chow

发表

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

Suzanne F. Jones, H. Burris, J. Infante, 2015, Investigational New Drugs.

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors

David A. Smith, D. V. Von Hoff, F. Braiteh, 2015, Investigational New Drugs.

Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure

K. Cassidy, P. Kulanthaivel, R. Barbuch, 2013, Drug Metabolism and Disposition.

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia

G. Borthakur, D. Rizzieri, L. Brail, 2016, Leukemia & lymphoma.

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

J. Machiels, Y. Bang, A. Italiano, 2021, Clinical Cancer Research.

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Y. Bang, A. Italiano, A. Patnaik, 2020, Clinical Cancer Research.

286 Tailored dosing of tasisulam-sodium (LY573636-sodium) to reduce hematologic toxicity and improve therapeutic index

D. Alwis, I. Trocóniz, R. Ilaria, 2010 .

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

C. Ernest, S. Shcherbinin, B. Willis, 2023, Clinical pharmacology and therapeutics.

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

C. Ernest, S. Shcherbinin, B. Willis, 2023, Alzheimer's & dementia.